Trial Profile

A Multicenter, Observational, Postmarketing Surveillance Study of Spinraza Injection (Nusinersen Sodium) When Used in Routine Medical Practice in Korea

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 17 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nusinersen (Primary)
Indications Spinal muscular atrophy
Focus Adverse reactions
Acronyms STANDARD
Sponsors Biogen

Most Recent Events

05 Oct 2020 Planned End Date changed from 11 May 2022 to 1 Jul 2027.
05 Oct 2020 Planned primary completion date changed from 11 May 2022 to 1 Jul 2027.
26 Mar 2020 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com